You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Autophagic Cell Death

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Trial in Wuhan (Cadonilimab, Pemetrexed, Carboplatin)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Wuhan, Hubei, China
    Qian Chu
Aug 18, 2023

NSCLC (NSCLC) Trial in Shanghai (Tumor treating fields(EFE-P100), Docetaxel injection)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • Tumor treating fields（EFE-P100）
  • Docetaxel injection
  • Shanghai, China
    Shanghai Pulmonary Hospital
Dec 21, 2022

NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +4 more
  • MK-2870
  • +2 more
  • (no location specified)
Sep 15, 2023

Cutaneous T-Cell Lymphoma, Graft Vs Host Disease, Graft Rejection Trial in Besançon (Samples collection)

Recruiting
  • Cutaneous T-Cell Lymphoma
  • +2 more
  • Samples collection
  • Besançon, France
    Centre Hospitalier Universitaire de Besançon
May 31, 2022

Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell

Recruiting
  • Primary Immune Deficiency
    • Bethesda, Maryland
    • +6 more
    Feb 2, 2023

    PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC

    Recruiting
    • Non-small Cell Lung Cancer
    • Monza, Italy
      ASST-Monza Ospedale San Gerardo
    Jun 9, 2022

    Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation Trial in Peking (Pembrolizumab, pemetrexed,

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • +2 more
    • Peking, China
      Peking Union Medical College Hospital
    Nov 16, 2023

    Cardiac Arrhythmias in Subjects Treated With BTK Inhibitors

    Recruiting
    • Chronic Lymphocytic Leukemia (CLL)
    • +5 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Feb 16, 2023

      Esophageal Squamous Cell Carcinoma Trial (Paclitaxel, Irinotecan, Pembrolizumab)

      Recruiting
      • Esophageal Squamous Cell Carcinoma
      • Chuo-ku, Tokyo, Japan
        National Cancer Center Hospital ( Site 3700)
      Jan 31, 2023

      Acute Lymphoblastic Leukemia in Pediatric Trial in Sohag (flow cytometric immunophynotyping)

      Not yet recruiting
      • Acute Lymphoblastic Leukemia in Pediatric
      • flow cytometric immunophynotyping
      • Sohag, Egypt
        Sohag University Hospital
      Jun 19, 2022

      Deeply Phenotype Major Organs in Sickle Cell Disease After

      Enrolling by invitation
      • Mortality in Sickle Cell
      • +4 more
        • Bethesda, Maryland
          National Institutes of Health Clinical Center
        Jul 13, 2022

        Tumor-Infiltrating Lymphocytes and Programmed Cell Death -

        Recruiting
        • Breast Cancer
        • +2 more
        • Observational Study
        • Lucknow, Uttar Pradesh, India
          Sanjay Gandhi Postgraduate Institute of Medical Sciences
        Feb 11, 2022

        Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma Trial in Changchun (Rituximab,

        Recruiting
        • Peripheral T-Cell Lymphoma, Not Otherwise Specified
        • Angioimmunoblastic T-cell Lymphoma
        • Changchun, Jilin, China
          The First Bethune Hospital of Jilin University
        Apr 7, 2023

        Anti-Programmed Cell Death Protein 1 Immunotherapy in Head and

        Recruiting
        • Head and Neck Cancer
        • Strasbourg, France
          Institut de cancérologie Strasbourg Europe
        Apr 14, 2022

        Metastatic Nonsmall Cell Lung Cancer, Non Small Cell Lung Cancer Trial in Philadelphia (Stereotactic Body Radiotherapy)

        Active, not recruiting
        • Metastatic Nonsmall Cell Lung Cancer
        • Non Small Cell Lung Cancer
        • Stereotactic Body Radiotherapy
        • Philadelphia, Pennsylvania
          Philadelphia CyberKnife
        Mar 15, 2022

        NSCLC Trial (pembrolizumab, carboplatin, paclitaxel)

        Active, not recruiting
        Has Results
        • Non-small Cell Lung Cancer
        • pembrolizumab
        • +3 more
        • (no location specified)
        Aug 18, 2022

        Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization, Tyrosine Kinase Inhibitor Trial in Chengdu (lenvatinib

        Enrolling by invitation
        • Hepatocellular Carcinoma Non-resectable
        • +3 more
        • lenvatinib + sindilimab/carrelizumab
        • TACE
        • Chengdu, Sichuan, China
          West China Hospital of Sichuan University
        May 23, 2022

        NSCLC Trial in Marietta, Taichung City, Tainan (Sacituzumab Govitecan, Pembrolizumab)

        Recruiting
        • Carcinoma, Non-Small-Cell Lung
        • Sacituzumab Govitecan
        • Pembrolizumab
        • Marietta, Georgia
        • +2 more
        Jan 27, 2023

        Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy Trial in Guangzhou (Toripalimab,

        Not yet recruiting
        • Muscle-Invasive Bladder Carcinoma
        • +2 more
        • Guangzhou, Guangdong, China
          Cancer Center, Sun Yat-sen University
        Aug 3, 2023

        NSCLC Trial (pembrolizumab, carboplatin, paclitaxel)

        Active, not recruiting
        Has Results
        • Non-small Cell Lung Cancer
        • pembrolizumab
        • +3 more
        • (no location specified)
        Aug 18, 2022

        Locally Advanced Cervical Cancer Trial in Villejuif (Atezolizumab, Radiotherapy, Cisplatin)

        Recruiting
        • Locally Advanced Cervical Cancer
        • Villejuif, Val De Marne, France
          Gustave Roussy
        Feb 15, 2022

        Pilon Fracture Trial in Columbia (N-acetylcysteine, Saline)

        Recruiting
        • Pilon Fracture
        • Columbia, Missouri
          University of Missouri Health System
        Nov 2, 2022

        Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Chapel Hill (Nivolumab, Pembrolizumab)

        Recruiting
        • Relapsed Hodgkin Lymphoma
        • Refractory Hodgkin Lymphoma
        • Nivolumab
        • Pembrolizumab
        • Chapel Hill, North Carolina
          Lineberger Comprehensive Cancer Center at University of North Ca
        Jul 22, 2022

        Malignant Melanoma Trial (tremelimumab/durvalumab, ipilimumab/nivolumab and nivolumab monotherapy)

        Withdrawn
        • Malignant Melanoma
        • tremelimumab/durvalumab, ipilimumab/nivolumab and nivolumab monotherapy
        • (no location specified)
        Nov 12, 2021

        Locally Advanced Basal Cell Carcinoma Trial in Philadelphia (biological, procedure, other)

        Not yet recruiting
        • Locally Advanced Basal Cell Carcinoma
        • Cemiplimab
        • +3 more
        • Philadelphia, Pennsylvania
          Thomas Jefferson University Hospital
        Jun 28, 2023